Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Coldstream Capital Management Inc.

Coldstream Capital Management Inc. lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 13.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,909 shares of the medical instruments supplier’s stock after purchasing an additional 459 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $938,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. State Street Corp raised its position in shares of Becton, Dickinson and Company by 0.8% during the 3rd quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock worth $3,364,096,000 after purchasing an additional 106,616 shares during the period. Geode Capital Management LLC raised its position in shares of Becton, Dickinson and Company by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock worth $1,510,050,000 after purchasing an additional 111,101 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of Becton, Dickinson and Company by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock worth $1,293,635,000 after purchasing an additional 460,440 shares during the period. Ameriprise Financial Inc. raised its position in shares of Becton, Dickinson and Company by 6.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock worth $1,181,483,000 after purchasing an additional 302,893 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of Becton, Dickinson and Company by 8.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after purchasing an additional 346,720 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction on Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the transaction, the executive vice president now directly owns 24,345 shares in the company, valued at approximately $5,380,488.45. This trade represents a 15.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.31% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms recently commented on BDX. Evercore ISI raised their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $283.50.

Becton, Dickinson and Company Stock Up 2.8 %

BDX opened at $227.17 on Friday. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $249.89. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The stock has a market cap of $65.68 billion, a P/E ratio of 37.21, a P/E/G ratio of 1.64 and a beta of 0.41. The stock’s 50 day moving average price is $231.46 and its 200 day moving average price is $233.40.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the firm earned $3.42 EPS. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, December 9th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a dividend yield of 1.83%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.